Similar to Mandarano’s conclusion that high expression of IDO2 correlated with poor non-small-cell lung cancer prognosis [30], we found that there is a significant difference of RFS between IDO2-high and IDO2-low MTC patients ( Fig. 2B). This evidence concerns the gene IDO2 and non-small cell lung carcinoma.